Trial Profile
Safety and efficacy of vedolizumab in patients with inflammatory bowel disease
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 10 Jul 2020
Price :
$35
*
At a glance
- Drugs Vedolizumab (Primary)
- Indications Crohn's disease; Inflammatory bowel diseases; Ulcerative colitis
- Focus Adverse reactions; Therapeutic Use
- 19 May 2020 Results (n=161) published in Gasteroenterology in conjunction with Digestive Disease Week 2020
- 13 Dec 2016 New trial record
- 19 Oct 2016 Results (n=72) presented at the 24th United European Gastroenterology Week.